Literature DB >> 25253157

Examination of the role of galectins in pre-mRNA splicing.

Ronald J Patterson1, Kevin C Haudek, Patricia G Voss, John L Wang.   

Abstract

Several lines of evidence have been accumulated to indicate that galectin-1 and galectin-3 are two of the many proteins involved in nuclear splicing of pre-mRNA. First, nuclear extracts, capable of carrying out splicing of pre-mRNA in a cell-free assay, contain both of the galectins. Second, depletion of the galectins from nuclear extracts, using either lactose affinity chromatography or immunoadsorption with antibodies, results in concomitant loss of splicing activity. Third, addition of either galectin-1 or galectin-3 to the galectin-depleted extract reconstitutes the splicing activity. Fourth, the addition of saccharides that bind to galectin-1 and galectin-3 with high affinity (e.g., lactose or thiodigalactoside) to nuclear extract results in inhibition of splicing whereas parallel addition of saccharides that do not bind to the galectins (e.g., cellobiose) fail to yield the same effect. Finally, when a splicing reaction is subjected to immunoprecipitation by antibodies directed against galectin-1, radiolabeled RNA species corresponding to the starting pre-mRNA substrate, the mature mRNA product, and intermediates of the splicing reaction are coprecipitated with the galectin. Similar results were also obtained with antibodies against galectin-3. This chapter describes two key assays used in our studies: one reports on the splicing activity by looking at product formation on a denaturing gel; the other reports on the intermediates of spliceosome assembly using non-denaturing or native gels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25253157     DOI: 10.1007/978-1-4939-1396-1_28

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments.

Authors:  Ana Carolina Ferreira Cardoso; Luciana Nogueira de Sousa Andrade; Silvina Odete Bustos; Roger Chammas
Journal:  Front Oncol       Date:  2016-05-23       Impact factor: 6.244

2.  A 10S galectin-3-U1 snRNP complex assembles into active spliceosomes.

Authors:  Kevin C Haudek; Patricia G Voss; John L Wang; Ronald J Patterson
Journal:  Nucleic Acids Res       Date:  2016-04-21       Impact factor: 16.971

3.  Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.

Authors:  Heiko Schulz; Elisa Schmoeckel; Christina Kuhn; Simone Hofmann; Doris Mayr; Sven Mahner; Udo Jeschke
Journal:  Int J Mol Sci       Date:  2017-06-08       Impact factor: 5.923

4.  A Truncated Galectin-3 Isolated from Skin Mucus of Atlantic Salmon Salmo salar Binds to and Modulates the Proteome of the Gram-Negative Bacteria Moritella viscosa.

Authors:  Deepti Manjari Patel; Yoichiro Kitani; Kjetil Korsnes; Martin Haugmo Iversen; Monica Fengsrud Brinchmann
Journal:  Mar Drugs       Date:  2020-02-04       Impact factor: 5.118

5.  Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome.

Authors:  Carolina Tiraboschi; Lucas Gentilini; Carla Velazquez; Enrique Corapi; Felipe Martín Jaworski; José Daniel Garcia Garcia; Yorfer Rondón; Anne Chauchereau; Diego José Laderach; Daniel Compagno
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

6.  Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.

Authors:  Helicia Paz; Eun Ji Joo; Chih-Hsing Chou; Fei Fei; Kevin H Mayo; Hisham Abdel-Azim; Haike Ghazarian; John Groffen; Nora Heisterkamp
Journal:  J Exp Clin Cancer Res       Date:  2018-03-27

7.  Expression, Regulation, and Functions of the Galectin-16 Gene in Human Cells and Tissues.

Authors:  Jennifer D Kaminker; Alexander V Timoshenko
Journal:  Biomolecules       Date:  2021-12-20

8.  Galectin-1 and -3 in high amounts inhibit angiogenic properties of human retinal microvascular endothelial cells in vitro.

Authors:  Anna Hillenmayer; Christian M Wertheimer; Arie Geerlof; Kirsten H Eibl; Siegfried Priglinger; Claudia Priglinger; Andreas Ohlmann
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.